Associate Professor of Anaesthesia, Brigham and Women's Hospital
Anesthesiology
Dr. Omid C. Farokhzad, MD
|
|
Give Review
Omid Farokhzad is an expert in the field of Anesthesiology. He researched medicine at Boston University School of Medicine. Boston University School of Medicine has a rank of 30 in research and a 52 in primary care Dr. Omid C. Farokhzad is also a published doctor. He has 73 paper published. The most recent paper is: Nanomedicines for Endothelial Disorders. Omid C. Farokhzad is registered with Medicare and accepts Medicare payments.
Publications
- Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle.
- Polymeric nanoparticle drug delivery technologies for oral delivery applications.
- Cancer nanomedicine: from targeted delivery to combination therapy.
- Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.
- A Solvent-Free Thermosponge Nanoparticle Platform for Efficient Delivery of Labile Proteins.
- Nanoparticles Containing a Liver X Receptor Agonist Inhibit Inflammation and Atherosclerosis.
- Engineered nanomedicine for myeloma and bone microenvironment targeting.
- Development of Multinuclear Polymeric Nanoparticles as Robust Protein Nanocarriers.
- Polymeric Nanoparticle Technologies for Oral Drug Delivery.
- Insight into nanoparticle cellular uptake and intracellular targeting.
- Ultra-High Throughput Synthesis of Nanoparticles with Homogeneous Size Distribution Using a Coaxial Turbulent Jet Mixer.
- Development of Therapeutic Polymeric Nanoparticles for the Resolution of Inflammation.
- Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic ...
- Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing.
- Current progress of aptamer-based molecular imaging.
- Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis.
- Microfluidic Platform for Combinatorial Synthesis and Optimization of Targeted Nanoparticles for Cancer Therapy.
- Transepithelial transport of fc-targeted nanoparticles by the neonatal fc receptor for oral delivery.
- Cancer nanotechnology: The impact of passive and active targeting in the era of modern Cancer biology.
- Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug.
- Single Step Reconstitution of Multifunctional High-Density Lipoprotein-Derived Nanomaterials Using Microfluidics.
- Parallel Microfluidic Synthesis of Size-Tunable Polymeric Nanoparticles Using 3D Flow Focusing towards In Vivo Study.
- Synthesis and in vitro evaluation of a multifunctional and surface-switchable nanoemulsion platform.
- Nanoparticle Encapsulation of Mitaplatin and the Effect Thereof on In Vivo Properties.
- Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles.
- Spontaneous Formation of Heterogeneous Patches on Polymer-Lipid Core-Shell Particle Surfaces during Self-Assembly.
- DNA Self-Assembly of Targeted Near-Infrared-Responsive Gold Nanoparticles for Cancer Thermo-Chemotherapy.
- Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.
- Microfluidic technologies for accelerating the clinical translation of nanoparticles.
- Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine.
- Mass Production and Size Control of Lipid-Polymer Hybrid Nanoparticles through Controlled Microvortices.
- α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug.
- Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities.
- Surface Charge-Switching Polymeric Nanoparticles for Bacterial Cell Wall-Targeted Delivery of Antibiotics.
- Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.
- Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile.
- Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection.
- In vivo prevention of arterial reStenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles.
- Self-Propelled Microrockets to Capture and Isolate Circulating Tumor Cells.
- Differentially Charged Hollow Core/Shell Lipid-Polymer-Lipid Hybrid Nanoparticles for Small Interfering RNA Delivery.
- Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation.
- Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles.
- Targeted delivery of a cisplatin prodrug for safer and more effective prostate Cancer therapy in vivo.
- Nanoparticle Delivery of Cancer Drugs.
- pH-Responsive nanoparticles for drug delivery.
- On firm ground: IP protection of therapeutic nanoparticles.
- Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.
- Nanotechnology in drug delivery and tissue engineering: from Discovery to applications.
- Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing.
- Spatiotemporal controlled delivery of nanoparticles to injured vasculature.
- Polymeric nanoparticles for drug delivery.
- Progress in siRNA delivery using multifunctional nanoparticles.
- Design of a mechanical clutch-based needle-insertion device.
- Impact of nanotechnology on drug delivery.
- Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery.
- Targeted delivery of cisplatin to prostate Cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
- Microfluidic platform for controlled synthesis of polymeric nanoparticles.
- Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform.
- Factors affecting the clearance and biodistribution of polymeric nanoparticles.
- Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.
- New frontiers in nanotechnology for Cancer treatment.
- Quantum dot-aptamer conjugates for synchronous Cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.
- Nanofabrication and microfabrication of functional materials for tissue engineering.
- Drug delivery systems in urology--getting "smarter".
- Targeted nanoparticle-aptamer bioconjugates for Cancer chemotherapy in vivo.
- Magnetically responsive polymeric microparticles for oral delivery of protein drugs.
- Microfluidic system for studying the interaction of nanoparticles and microparticles with cells.
- Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate Cancer cells.
- CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junD.
- During differentiation of the monocytic cell line U937, Pur alpha mediates induction of the CD11c beta 2 integrin gene promoter.
- Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug.
- Nanomedicines for Endothelial Disorders.
Schools
Boston University School Of Medicine
Beth Israel Deaconess Med Center
Brigham and Women39s Hospital
Procedures Preformed
- Epidural Block, Facet Blocks
- Myofascial Trigger Point Injection
- Nerve Block, Somatic
- Nerve Destruction by Neurolytic Agent
- View All
Conditions Treated
- Autonomic Disorders
- Back Pain
- Benign Chronic Pain Syndrome
- Brachial Plexus Palsy
- View All
Doctors Specialties
- Pain Medicine
- Anesthesiology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Beth Israel Deaconess Medical Center -
Boston University School of Medicine
Hospital
-
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1548241433 | |
| NPPES Provider LastName | FAROKHZAD | |
| NPPES Provider FirstName | OMID | |
| NPPES Provider ZIPCode | 021156110 | |
| NPPES Provider State | MA | |
| Specialty Description | Anesthesiology | |
| Total Claim Count | 51.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 29.41 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1548241433 |
| Last Name Of The Provider | FAROKHZAD |
| First Name Of The Provider | OMID |
| View All |
Similar Doctors
|
|
David J. Glover, MB CHB
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ehren R. Nelson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brendan T. McGinn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monica A. Lupo, MD |
|
|
Dr. Anjali Koka, MD |
|
|
Dr. Jeremy C. Jones, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen R. Heape, MD |
|
|
Dr. Joseph T. Gundy, MD |
|
|
Dr. Terence K. Gray, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie H. Huang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert J. Yong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Assia T. Valovska, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edgar L. Ross, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jamit S. Dhaliwal, MD |